Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors: A Case Report

Luca Filippi, Alida Ciorra, Barbara Sardella, Orazio Schillaci, Oreste Bagni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

90Y radioembolization and peptide-receptor radionuclide therapy (PRRT) with177Lu-DOTATATE are both effective treatments for patients with inoperable neuroendocrine metastatic tumors (NET). We report the case of a 72-year-old man with severe functional syndrome due to a metastatic NET. 68Ga-DOTATOC positron-emission tomography (PET) revealed high somatostatin receptor expression in a gross liver metastasis, in one abdominal lymph node and in several skeletal lesions. The patient underwent liver radioembolization with 90Y-resin microspheres followed by four cycles of PRRT with177Lu-DOTATATE. After 3 months, a complete remission of the functional syndrome was observed. 68Ga-DOTATOC PET demonstrated a complete response for skeletal and lymph nodal lesions with a residual bulky mass in the liver. Therefore a further 90Y radioembolization was performed as consolidation treatment for the hepatic lesion. Six months after these combined treatments, 68Ga-DOTATOC PET demonstrated complete metabolic response in liver and stable extrahepatic lesions. No significant long-term adverse reactions were registered. To our knowledge, the sequential use of 90Y radiembolization before and after PRRT in a liver-dominant advanced NET has not been reported in the literature and this case suggests that these combined treatments can be safe and effective.

Original languageEnglish
Pages (from-to)321-325
Number of pages5
JournalNuclear Medicine and Molecular Imaging
Volume48
Issue number4
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Neuroendocrine Tumors
Microspheres
Peptide Receptors
Liver
Radioisotopes
Positron-Emission Tomography
Therapeutics
Somatostatin Receptors
Lymph
Lymph Nodes
Neoplasm Metastasis
Ga(III)-DOTATOC

Keywords

  • Lu DOTATATE
  • Y radioembolization
  • Neuroendocrine tumors
  • Somatostatin receptors

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors : A Case Report. / Filippi, Luca; Ciorra, Alida; Sardella, Barbara; Schillaci, Orazio; Bagni, Oreste.

In: Nuclear Medicine and Molecular Imaging, Vol. 48, No. 4, 01.12.2014, p. 321-325.

Research output: Contribution to journalArticle

Filippi, Luca ; Ciorra, Alida ; Sardella, Barbara ; Schillaci, Orazio ; Bagni, Oreste. / Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors : A Case Report. In: Nuclear Medicine and Molecular Imaging. 2014 ; Vol. 48, No. 4. pp. 321-325.
@article{1e7364bcdd564fc7a078343f00502897,
title = "Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors: A Case Report",
abstract = "90Y radioembolization and peptide-receptor radionuclide therapy (PRRT) with177Lu-DOTATATE are both effective treatments for patients with inoperable neuroendocrine metastatic tumors (NET). We report the case of a 72-year-old man with severe functional syndrome due to a metastatic NET. 68Ga-DOTATOC positron-emission tomography (PET) revealed high somatostatin receptor expression in a gross liver metastasis, in one abdominal lymph node and in several skeletal lesions. The patient underwent liver radioembolization with 90Y-resin microspheres followed by four cycles of PRRT with177Lu-DOTATATE. After 3 months, a complete remission of the functional syndrome was observed. 68Ga-DOTATOC PET demonstrated a complete response for skeletal and lymph nodal lesions with a residual bulky mass in the liver. Therefore a further 90Y radioembolization was performed as consolidation treatment for the hepatic lesion. Six months after these combined treatments, 68Ga-DOTATOC PET demonstrated complete metabolic response in liver and stable extrahepatic lesions. No significant long-term adverse reactions were registered. To our knowledge, the sequential use of 90Y radiembolization before and after PRRT in a liver-dominant advanced NET has not been reported in the literature and this case suggests that these combined treatments can be safe and effective.",
keywords = "Lu DOTATATE, Y radioembolization, Neuroendocrine tumors, Somatostatin receptors",
author = "Luca Filippi and Alida Ciorra and Barbara Sardella and Orazio Schillaci and Oreste Bagni",
year = "2014",
month = "12",
day = "1",
doi = "10.1007/s13139-014-0292-2",
language = "English",
volume = "48",
pages = "321--325",
journal = "Nuclear Medicine and Molecular Imaging",
issn = "1869-3474",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors

T2 - A Case Report

AU - Filippi, Luca

AU - Ciorra, Alida

AU - Sardella, Barbara

AU - Schillaci, Orazio

AU - Bagni, Oreste

PY - 2014/12/1

Y1 - 2014/12/1

N2 - 90Y radioembolization and peptide-receptor radionuclide therapy (PRRT) with177Lu-DOTATATE are both effective treatments for patients with inoperable neuroendocrine metastatic tumors (NET). We report the case of a 72-year-old man with severe functional syndrome due to a metastatic NET. 68Ga-DOTATOC positron-emission tomography (PET) revealed high somatostatin receptor expression in a gross liver metastasis, in one abdominal lymph node and in several skeletal lesions. The patient underwent liver radioembolization with 90Y-resin microspheres followed by four cycles of PRRT with177Lu-DOTATATE. After 3 months, a complete remission of the functional syndrome was observed. 68Ga-DOTATOC PET demonstrated a complete response for skeletal and lymph nodal lesions with a residual bulky mass in the liver. Therefore a further 90Y radioembolization was performed as consolidation treatment for the hepatic lesion. Six months after these combined treatments, 68Ga-DOTATOC PET demonstrated complete metabolic response in liver and stable extrahepatic lesions. No significant long-term adverse reactions were registered. To our knowledge, the sequential use of 90Y radiembolization before and after PRRT in a liver-dominant advanced NET has not been reported in the literature and this case suggests that these combined treatments can be safe and effective.

AB - 90Y radioembolization and peptide-receptor radionuclide therapy (PRRT) with177Lu-DOTATATE are both effective treatments for patients with inoperable neuroendocrine metastatic tumors (NET). We report the case of a 72-year-old man with severe functional syndrome due to a metastatic NET. 68Ga-DOTATOC positron-emission tomography (PET) revealed high somatostatin receptor expression in a gross liver metastasis, in one abdominal lymph node and in several skeletal lesions. The patient underwent liver radioembolization with 90Y-resin microspheres followed by four cycles of PRRT with177Lu-DOTATATE. After 3 months, a complete remission of the functional syndrome was observed. 68Ga-DOTATOC PET demonstrated a complete response for skeletal and lymph nodal lesions with a residual bulky mass in the liver. Therefore a further 90Y radioembolization was performed as consolidation treatment for the hepatic lesion. Six months after these combined treatments, 68Ga-DOTATOC PET demonstrated complete metabolic response in liver and stable extrahepatic lesions. No significant long-term adverse reactions were registered. To our knowledge, the sequential use of 90Y radiembolization before and after PRRT in a liver-dominant advanced NET has not been reported in the literature and this case suggests that these combined treatments can be safe and effective.

KW - Lu DOTATATE

KW - Y radioembolization

KW - Neuroendocrine tumors

KW - Somatostatin receptors

UR - http://www.scopus.com/inward/record.url?scp=84957586191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957586191&partnerID=8YFLogxK

U2 - 10.1007/s13139-014-0292-2

DO - 10.1007/s13139-014-0292-2

M3 - Article

AN - SCOPUS:84957586191

VL - 48

SP - 321

EP - 325

JO - Nuclear Medicine and Molecular Imaging

JF - Nuclear Medicine and Molecular Imaging

SN - 1869-3474

IS - 4

ER -